HK1248133A1 - 治疗神经母细胞瘤的方法 - Google Patents

治疗神经母细胞瘤的方法 Download PDF

Info

Publication number
HK1248133A1
HK1248133A1 HK18107762.1A HK18107762A HK1248133A1 HK 1248133 A1 HK1248133 A1 HK 1248133A1 HK 18107762 A HK18107762 A HK 18107762A HK 1248133 A1 HK1248133 A1 HK 1248133A1
Authority
HK
Hong Kong
Prior art keywords
cancer
patients
methods
neuroblastoma
linked
Prior art date
Application number
HK18107762.1A
Other languages
English (en)
Chinese (zh)
Inventor
Eugene Gerner
Elizabeth Bruckheimer
Original Assignee
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Cancer Prevention Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Arizona Board Of Regents On Behalf Of The University Of Arizona, Cancer Prevention Pharmaceuticals, Inc. filed Critical The Arizona Board Of Regents On Behalf Of The University Of Arizona
Publication of HK1248133A1 publication Critical patent/HK1248133A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18107762.1A 2015-02-12 2016-02-12 治疗神经母细胞瘤的方法 HK1248133A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115413P 2015-02-12 2015-02-12
US62/115,413 2015-02-12
US201562154804P 2015-04-30 2015-04-30
US62/154,804 2015-04-30
PCT/US2016/017751 WO2016130918A1 (en) 2015-02-12 2016-02-12 Methods for treating neuroblastoma

Publications (1)

Publication Number Publication Date
HK1248133A1 true HK1248133A1 (zh) 2018-10-12

Family

ID=56615061

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107762.1A HK1248133A1 (zh) 2015-02-12 2016-02-12 治疗神经母细胞瘤的方法

Country Status (6)

Country Link
US (4) US20190046484A1 (https=)
EP (1) EP3256117A4 (https=)
JP (1) JP2018507910A (https=)
CA (1) CA2976106A1 (https=)
HK (1) HK1248133A1 (https=)
WO (1) WO2016130918A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015195120A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
KR20260033630A (ko) 2015-10-30 2026-03-10 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
US12042477B2 (en) 2016-02-23 2024-07-23 Cancer Research Technology Limited Dietary product devoid of at least two non essential amino acids
JP7262118B2 (ja) * 2016-10-06 2023-04-21 オーバス セラピューティクス インコーポレイテッド 医薬組成物およびその使用
CN113164414A (zh) * 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
JP2022532766A (ja) * 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
US12220402B2 (en) 2020-06-03 2025-02-11 Faeth Therapeutics, Inc. Formulations for personalized methods of treatment
WO2021247923A1 (en) 2020-06-04 2021-12-09 Faeth Therapeutics, Inc. Personalized methods of treating cancer
CN120548176A (zh) 2022-11-20 2025-08-26 苏黎士大学 多胺途径抑制剂药物与脯氨酸/精氨酸饮食限制的组合
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
AU5200098A (en) 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
WO1998025603A1 (en) 1996-12-13 1998-06-18 Ilex Oncology, Inc. Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
CA2325080A1 (en) 1998-03-28 1999-10-07 The Regents Of The University Of California Dfmo and sulindac combination in cancer chemoprevention
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
KR20010079913A (ko) * 1998-09-23 2001-08-22 토마스 케플러, 자비네 루츠 (-)-α-(디플루오로메틸)오르니틴-모노히드로클로라이드일수화물의 제조 방법
US6753422B2 (en) * 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
AU2001285232A1 (en) 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
US6730809B2 (en) * 2001-08-29 2004-05-04 Women First Healthcare, Inc. Processes for the production of α-difluoromethyl ornithine (DFMO)
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
MXPA05005781A (es) 2002-11-29 2005-12-12 Forest Laboratories Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
PL1706428T3 (pl) * 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US20100009929A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
WO2007075673A1 (en) * 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
ES2380747T3 (es) 2006-07-18 2012-05-18 Horizon Pharma Usa, Inc. Métodos y medicamentos para administración de ibuprofeno
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
SG183010A1 (en) * 2007-08-01 2012-08-30 Sigma Tau Ind Farmaceuti Treatment of pediatric tumors
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
US20100120727A1 (en) 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
AU2009333510A1 (en) 2008-12-08 2011-06-30 The Procter & Gamble Company Personal care composition in the form of an article having a hydrophobic surface-resident coating
DK2430452T3 (da) * 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
CN102802729A (zh) * 2009-05-20 2012-11-28 兰贝克赛实验室有限公司 异维a酸的液体剂型
US20110256161A1 (en) * 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
CA2800557A1 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
DK3323830T3 (da) * 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
CA2889711A1 (en) * 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
GB2513299A (en) * 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
WO2015195120A1 (en) * 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation

Also Published As

Publication number Publication date
EP3256117A4 (en) 2018-10-10
US20190046484A1 (en) 2019-02-14
US12582625B2 (en) 2026-03-24
CA2976106A1 (en) 2016-08-18
WO2016130918A1 (en) 2016-08-18
JP2018507910A (ja) 2018-03-22
US20250127742A1 (en) 2025-04-24
US20240165063A1 (en) 2024-05-23
US20210378999A1 (en) 2021-12-09
EP3256117A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
HK1248133A1 (zh) 治疗神经母细胞瘤的方法
WO2019226514A3 (en) Molecular gene signatures and methods of using same
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
WO2014145751A3 (en) Targeted therapies for cancer
Jin et al. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer
MX2021011677A (es) Uso del gen kdm5a y del gen atrx.
WO2012075472A3 (en) Chemical entities and therapeutic uses thereof
Choi et al. Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis
Bredeson Intravenous versus oral busulfan-based conditioning for pediatric allogeneic hematopoietic cell transplantations: did the pendulum swing too far, too fast?
Zepeda Dexamethasone/pomalidomide
Mathisen et al. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
Finke et al. Randomized trial on GvHD prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in allogeneic hematopoietic cell transplantation from matched unrelated donors: final long-term results after 8.6 years median follow-up
Morais et al. Evaluation of ANXA11 rs1049550 SNP linkage with sarcoidosis susceptibility
CA2941666C (en) Fibroblast growth factor-2 (fgf2) and syndecan-1 (sdc1) as biomarkers for poor outcome hodgkin lymphoma patients
Karavasilis Thromboembolic event: case report
Mauro et al. Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR4. 5) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update
Hughes Brentuximab vedotin/immune globulin
Yagasaki et al. Improved Outcome of Unrelated Bone Marrow Transplantation for Severe Aplastic Anemia.
UA104418U (uk) Спосіб прогнозування зрощення перелому
Vázquez et al. PP143—Impact of UGT1A4 genotype in the clinical response to lamotrigine in patients with epilepsy
Yanagihara Allergic reaction and fever: 2 case reports
Grenader Diarrhoea: case report
UA100390U (ru) Способ прогнозирования сращения перелома